Material Event Form 8 K

Item 7.01 Regulation FD Disclosure.

On July 15, 2024, Revolution Medicines, Inc. (the "Company") informed investors that it expects its net loss for the year ended December 31, 2024 to be between $560 million and $600 million, which includes estimated non-cashstock-based compensation expense of approximately $70 million to $80 million. The Company confirmed that it continues to project that current cash, cash equivalents and marketable securities can fund planned operations into 2027.

The information in this Item 7.01 of this Current Report on Form 8-Kshall not be deemed "filed" under the Securities Act of 1934, as amended (the "Exchange Act"), nor shall it be incorporated by reference into any future filings under the Securities Act of 1933, as amended (the "Securities Act"), or under the Exchange Act unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.